全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

Disease Prevention and Alleviation by Human Myoblast Transplantation

DOI: 10.4236/ojrm.2016.52003, PP. 25-43

Keywords: Human Gene Therapy, Myoblasts, Muscular Dystrophies, Heart Failure, Ischemic Cardiomyopathy, Type II Diabetes, Anti-Aging, Cosmetology, Muscle Regeneration and Repair

Full-Text   Cite this paper   Add to My Lib

Abstract:

Myoblast implantation is a unique, patented technology of muscle regeneration being tested in Phase III clinical trials of muscular dystrophy, ischemic cardiomyopathy, Phase II trial of cancer, and Phase I trial of Type II diabetes. Differentiated and committed, myoblasts are not stem cells. Implanted myoblasts fuse spontaneously among themselves, replenishing genetically normal myofibers. They also fuse with genetically abnormal myofibers of muscular dystrophy, cardiomyopathy, or Type II diabetes, transferring their nuclei containing the normal human genome to provide stable, long-term expression of the missing gene products. They develop to become cardiomyocytes in the infracted myocardium. Myoblasts transduced with VEGF165 allow concomitant regeneration of blood capillaries and myofibers. They are potent biologics for treating heart failure, ischemic cardiomyopathy, diabetic ischemia, erectile dysfunction, and baldness. Myoblasts, because of their small size, spindle shape, and resilience, can grow within wrinkles and on skin surfaces, thus enhancing the color, luster and texture of the skin “plated” with them. They can be injected subcutaneously as a cellular filler to reduce wrinkles. Intramuscular injection of myoblasts can augment the size, shape, consistency, tone and strength of muscle groups, improving the lines, contours and vitality to sculpt a youthful appearance. This highly promising technology has great social economic values in treating hereditary, fatal and debilitating disease conditions.

 References

[1]  DeLisi, C. (1988) The Human Genome Project. American Scientist, 76, 488-493.
[2]  Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., et al. (2001) The Sequence of the Human Genome. Science, 291, 1304-1351.
http://dx.doi.org/10.1126/science.1058040
[3]  Venter, D. (2003) A Part of the Human Genome Sequence. Science, 299, 1183-1184.
http://dx.doi.org/10.1126/science.299.5610.1183
[4]  White House Press Release. Retrieved 22 July 2006.
[5]  DeLisi, C. (2008) Meetings That Changed the World: Santa Fe 1986: Human Genome Baby-Steps. Nature, 455, 876-877.
http://dx.doi.org/10.1038/455876a
[6]  Collins, F. (2006) The Language of God: A Scientist Presents Evidence for Belief. Free Press, New York.
[7]  Beardsley, T. (1990) Profile: Gene Doctor. W. French Anderson Pioneers Gene Therapy. Scientific American, 263, 33-33B.
[8]  Anderson, W.F. (1990) Editorial. The beginning. Human Gene Therapy, 1, 371-372.
http://dx.doi.org/10.1089/hum.1990.1.4-371
[9]  Culver, K.W., Osborne, W.R., Miller, A.D., Fleisher, T.A., Berger, M., Anderson, W.F., et al. (1991) Correction of ADA Deficiency in Human T Lymphocytes Using Retroviral-Mediated Gene Transfer. Transplantation Proceedings, 23, 170-171.
[10]  Karlsson, S. (1991) Treatment of Genetic Defects in Hematopoietic Cell Function by Gene Transfer. Blood, 78, 2481-2492.
[11]  Anderson, W.F. (1992) Human Gene Therapy. Science, 256, 808-813.
http://dx.doi.org/10.1126/science.1589762
[12]  Culver, K.W. (1996) The First Human Gene Therapy Experiment. In: Culver, K.W., Ed., Gene Therapy: A Primer for Physicians, Mary Ann Liebert, Inc., New York, 47-53.
[13]  Gonzaga-Jauregui, C., Lupski, J.R. and Gibbs, R.A. (2012) Human Genome Sequencing in Health and Disease. Annual Review of Medicine, 63, 35-61.
http://dx.doi.org/10.1146/annurev-med-051010-162644
[14]  Snyder, M., Du, J. and Gerstein, M. (2012) Personal Genome Sequencing: Current Approaches and Challenges. Genes & Development, 24, 423-431.
http://dx.doi.org/10.1101/gad.1864110
[15]  (2012) GIA Announcement. San Jose, California (PRWEB), 28 February 2011.
[16]  Pearson, S., Jia, H. and Kandachi, K. (2004) China Approves First Gene Therapy. Nature Biotechnology, 22, 3-4.
http://dx.doi.org/10.1038/nbt0104-3
[17]  Liang, M. (2012) Clinical Development of Oncolytic Viruses in China. Current Pharmaceutical Biotechnology, 13, 1852-1857.
http://dx.doi.org/10.2174/138920112800958760
[18]  Yla-Herttuala, S. (2012) Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union. Molecular Therapy, 20, 1831-1832.
http://dx.doi.org/10.1038/mt.2012.194
[19]  Brenner, M.K. (1995) Human Somatic Gene Therapy: Progress and Problems. Journal of Internal Medicine, 237, 229-239.
http://dx.doi.org/10.1111/j.1365-2796.1995.tb01171.x
[20]  Crystal, R.G. (1997) Transfer of Genes to Humans: Early Lesions and Obstacles to Success. Science, 270, 404-410.
http://dx.doi.org/10.1126/science.270.5235.404
[21]  Verma, I. and Somia, N. (1997) Gene Therapy—Promises, Problems and Prospects. Nature, 389, 239-242.
http://dx.doi.org/10.1038/38410
[22]  Law, P.K., Goodwin, T.G., Fang, Q., Vastagh, G., Jordan, T., Jackson, T., et al. (1998) Myoblast Transfer as a Platform Technology of Gene Therapy. Gene Therapy and Molecular Biology, 1, 345-363.
[23]  Law, P.K., Ye, L., Haider, H.Kh., Lu, P., Law, D.M. and Sim, K.E.W. (2012) Therapeutic Angiomyo-genesis Using Human Non-Viral Transduced VEGF165-Myoblasts. Open Journal of Regenerative Medicine, 1, 1-9.
http://dx.doi.org/10.4236/ojrm.2012.11001
[24]  Thomas, C.E., Ehrhardt, A. and Kay, M.A. (2003) Progress and Problems with the Use of Viral Vectors for Gene Therapy. Nature Reviews Genetics, 4, 346-358.
http://dx.doi.org/10.1038/nrg1066
[25]  Law, P.K. (1992) Myoblast Transplantation. Science, 257, 1329.
http://dx.doi.org/10.1126/science.1529325
[26]  Furlong, T.E. (1992) Myoblast Transplantation. Science, 257, 1329.
http://dx.doi.org/10.1126/science.1529325
[27]  Law, P.K. and Law, D.M. (2011) Human Myoblast Genome Therapies and Devices in Regenerative Medicine. Recent Patents on Regenerative Medicine, 1, 88-117.
http://dx.doi.org/10.2174/2210296511101010088
[28]  Kessler, D.A., Siegel, J.P., Noguchi, P.D., Zoon, K.C., Feiden, K.L. and Woodcock, J. (1993) Regulation of Somatic Cell-Therapy and Gene Therapy by the Food and Drug Administration. The New England Journal of Medicine, 329, 1169-1173.
http://dx.doi.org/10.1056/NEJM199310143291607
[29]  (2013) William French Anderson. Wikipedia.
https://en.wikipedia.org/wiki/William_French_Anderson
[30]  Anderson, W.F. (1995) Gene Therapy. Scientific American, 273, 96-8B.
[31]  Kartalov, E.P., Anderson, W.F. and Scherer, A. (2006) The Analytical Approach to Polydimethylsiloxane Microfluidic Technology and Its Biological Applications. Journal of Nanoscience and Nanotechnology, 6, 2265-2277.
http://dx.doi.org/10.1166/jnn.2006.504
[32]  Stolberg, S.G. (1999) The Biotech Death of Jesse Gelsinger. New York Times Magazine.
[33]  Morsy, M.A. and Caskey, C.T. (1997) Safe Gene Vectors Made Simpler. Nature Biotechnology, 15, 17.
http://dx.doi.org/10.1038/nbt0197-17a
[34]  Coutelle, C., Caplen, N., Hart, S., et al. (1994) Towards Gene Therapy for Cystic Fibrosis. In: Dodge, J.A., Brock, J.H., and Widdicombe, J.H., Eds., Cystic Fibrosis Current Topics, Vol. 2, John Wiley and Sons, New York, 33-54.
[35]  Curiel, D.T., Pilewski, J.M. and Albelda, S. (1996) Gene Therapy Approaches for Inherited and Acquired Lung Diseases. American Journal of Respiratory Cell and Molecular Biology, 14, 1-18.
http://dx.doi.org/10.1165/ajrcmb.14.1.8534480
[36]  Knowles, M.R., Hohneker, K., Zhou, Z.Q., et al. (1995) A Double Blind Vehicle-Controlled Study of Adenoviral Mediated Gene Transfer in the Nasal Epithelium of Patients with Cystic Fibrosis. The New England Journal of Medicine, 333, 823-831.
http://dx.doi.org/10.1056/NEJM199509283331302
[37]  Stewart, M.J., Plautz, G.E., Del Buono, L., et al. (1992) Gene Transfer in Vivo with DNA-Liposome Complexes Safety and Acute Toxicity in Mice. Human Gene Therapy, 3, 267-275.
http://dx.doi.org/10.1089/hum.1992.3.3-267
[38]  Trubetskoy, V.S., Torchilin, V.P., Kennel, S.J., et al. (1992) Cationic Liposomes Enhance Targeted Delivery and Expression of Exogenous DNA Mediated by N-Terminal Modified Poly-L-Lysine-Antibody Conjugate in Mouse Lung Endothelial Cells. Biochimica et Biophysica Acta, 1131, 311-313.
http://dx.doi.org/10.1016/0167-4781(92)90030-4
[39]  Ye, L., Haider, H.K.H., Tan, R., Su, L., Law, P.K., Zhang, W., et al. (2008) Angiomyogenesis Using Liposome Based Vascular Endothelial Growth Factor-165 Transfection with Skeletal Myoblast for Cardiac Repair. Biomaterials, 29, 2125-2137.
http://dx.doi.org/10.1016/j.biomaterials.2008.01.014
[40]  Ye, L., Haider, H., Tan, R., Toh, W., Law, P.K., Tan, W., Su, L., Zhang, W., Ge, R., Zhang, Y., Lim, Y. and Sim, E.K. (2007) Transplantation of Nanoparticle Transfected Skeletal Myoblasts Overexpressing Vascular Endothelial Growth Factor-165 for Cardiac Repair. Circulation, 116, 1113-1120.
http://dx.doi.org/10.1161/CIRCULATIONAHA.106.680124
[41]  Wolff, I.A., Malone, R.W., Williams, P., et al. (1990) Direct Gene Transfer into Mouse Muscle in Vivo. Science, 247, 1465-1468.
http://dx.doi.org/10.1126/science.1690918
[42]  Ascadi, G., Dickson, G., Loves, D.R., et al. (1991) Human Dystrophin Expression in mdx Mice after Intramuscular Injection of DNA Constructs. Nature, 352, 815-818.
http://dx.doi.org/10.1038/352815a0
[43]  Davis, H.L., Whalen, R.G. and Demeneix, B.A. (1993) Direct Gene Transfer into Skeletal Muscles in Vivo, Factors Affecting Efficiency of Transfer and Stability of Expression. Human Gene Therapy, 4, 151-159.
http://dx.doi.org/10.1089/hum.1993.4.2-151
[44]  Lin, H., Parmacek, M.S., Morle, G., Bolling, S. and Leiden, J.M. (1991) Expression of Recombinant Genes in Myocardium in Vivo after Direct Injection of DNA. Circulation, 82, 2217-2221.
http://dx.doi.org/10.1161/01.CIR.82.6.2217
[45]  Wolff, I.A., Williams, P., Ascadi, G., et al. (1991) Conditions Affecting Direct Gene Transfer into Rodent Muscle in Vivo. BioTechniques, 11, 474-485.
[46]  Law, P.K., Bertorini, T., Goodwin, T.G., Chen, M., Fang, Q.W., Li, H.J., et al. (1990) Dystrophin Production Induced by Myoblast Transfer Therapy in Duchenne Muscular Dystrophy. The Lancet, 336, 114-115.
http://dx.doi.org/10.1016/0140-6736(90)91628-N
[47]  Ye, L., Lee, K.O., Su, L.P., Toh, W.C., Haider, H.K., Law, P.K., Zhang, W., Chan, S.P. and Sim, E.K.W. (2009) Skeletal Myoblast Transplantation for Attenuation of Hyperglycaemia, Hyperinsulinaemia and Glucose Intolerance in a Mouse Model of Type 2 Diabetes Mellitus. Diabetologia, 52, 1925-1934.
http://dx.doi.org/10.1007/s00125-009-1421-9
[48]  Ma, J.H., Su, L.P., Zhu, J., Law, P.K., Lee, K.O., Ye, L. and Wang, Z.Z. (2013) Skeletal Myoblast Transplantation on Gene Expression Profiles of Insulin Signaling Pathway and Mitochondrial Biogenesis and Function in Skeletal Muscle. Diabetes Research and Clinical Practice, 102, 43-52.
http://dx.doi.org/10.1016/j.diabres.2013.08.006
[49]  Law, P.K., Law, D.L.M., Lu, P., Guo, J., Lu, Y., Xue, Y.F. and Li, X. (2004) The World’s First Myoblast Study of Type II Diabetic Patients. Business Briefing: North American Pharmacotherapy, No. 2.
[50]  Law, P.K., Goodwin, T.G., Fang, Q., Duggirala, V., Larkin, C., Florendo, J.A., et al. (1992) Feasibility, Safety, and Efficacy of Myoblast Transfer Therapy on Duchenne Muscular Dystrophy Boys. Cell Transplantation, 1, 235-244.
[51]  Law, P.K., Goodwin, T.G., Fang, Q., Chen, M., Li, H.J., Florendo, J.A., et al. (1991) Pioneering Development of Myoblast Transfer Therapy. In: Angelini, C., Danieli, G.A. and Fontanari, D., Eds., Muscular Dystrophy Research, Elsevier Science Publishers, New York, 109-116.
[52]  Law, P.K., Goodwin, T.G., Fang, Q., Chen, M., Li, H.J., Florendo, J.A., et al. (1991) Long-Term Improvement in Muscle Function, Structure and Biochemistry Following Myoblast Transfer in DMD. Acta Cardiomiologica, 1, 281-301.
[53]  Law, P.K., Goodwin, T.G., Fang, Q., Deering, M.B., Duggirala, V., Larkin, C., et al. (1993) Cell Transplantation as an Experimental Treatment for Duchenne Muscular Dystrophy. Cell Transplantation, 2, 485-505.
[54]  Law, P.K., Goodwin, T.G., Fang, Q., Hall, T.L., Quinley, T., Vastagh, G., et al. (1997) First Human Myoblast Transfer Therapy Continues to Show Dystrophin after 6 Years. Cell Transplantation, 6, 95-100.
http://dx.doi.org/10.1016/S0963-6897(96)00138-8
[55]  Law, P.K., Sim, E.K.W., Haider, Kh.H., Feng, G., Chua, F., Kakuchaya, T., et al. (2004) Myoblast Genome Therapy and the Regenerative Heart. In: Kipshidze, N.N. and Serruys, P.W., Eds., Handbook of Cardiovascular Cell Transplantation, Dunitz Ltd., London, 241-257.
[56]  Haider, H.Kh., Jiang, S.J., Ye, L., Aziz, S., Law, P.K. and Sim, E.K. (2004) Effectiveness of Transient Immunosuppression Using Cyclosporine for Xenomyoblast Transplantation for Cardiac Repair. Transplantation Proceedings, 36, 232-235.
http://dx.doi.org/10.1016/j.transproceed.2003.11.001
[57]  Beutner, F., Teupser, D., Gielen, S., Holdt, L.M., Scholz, M., Boudriot, E., Schuler, G. and Thiery, J. (2011) Rationale and Design of the Leipzig (LIFE) Heart Study: Phenotyping and Cardiovascular Characteristics of Patients with Coronary Artery Disease. PLoS ONE, 6, e29070.
http://dx.doi.org/10.1371/journal.pone.0029070
[58]  Alavantic, D. and Djuric, T. (2006) Risk Factors of Atherosclerosis: A Review of Genetic Epidemiology Data from a Serbian Population. Experimental & Clinical Cardiology, 11, 78-82.
[59]  Law, P.K., Haider, K., Fang, G., Jiang, S., Chua, F., Lim, Y.T., et al. (2002) Mechanisms of Myoblast Transfer in Treating Heart Failure. In: Kimchi, A., Ed., Advances in Heart Failure, Medimond Medical Publications, Bologna, Italy, 43-48.
[60]  Law, P.K. (2002) The Regenerative Heart. Business Briefing: PharmTech, 65-71.
[61]  Law, P.K., Haider, K., Fang, G., Jiang, S., Chua, F., Lim, Y.T., et al. (2004) Human VEGF165-Myoblasts Produce Concomitant Angiogenesis/Myogenesis in the Regenerative Heart. Molecular and Cellular Biochemistry, 263, 173-178.
http://dx.doi.org/10.1023/B:MCBI.0000041859.60354.f5
[62]  Ye, L., Haider, H.Kh., Jiang, S., Ge, R., Law, P.K. and Sim, E.K. (2005) In Vitro Functional Assessment of Human Skeletal Myoblasts after Transduction with Adenoviral Bicistronic Vector Carrying Human VEGF165 and Angiopoietin-1. The Journal of Heart and Lung Transplantation, 24, 1393-1402.
http://dx.doi.org/10.1016/j.healun.2004.06.004
[63]  Law, P.K., Leo, A.B., Lu, P., Liew, C.-C., Law, D.M., Sim, E.K.W., et al. (2006) Human Myoblast Genome Therapy. Journal of Geriatric Cardiology, 3, 135-151.
[64]  Hagege, A.A., Carrion, C., Menasché, P., Vilquin, J.T., Duboc, D., Marolleau, J.P., et al. (2003) Viability and Differentiation of Autologous Skeletal Myoblast Grafts in Ischemic Cardiomyopathy. The Lancet, 361, 491-492.
http://dx.doi.org/10.1016/S0140-6736(03)12458-0
[65]  Pagani, F.D., DerSimonian, H., Zawadzka, A., Wetzel, K., Edge, A.S., Jacoby, D.B., et al. (2003) Autologous Skeletal Myoblasts Transplanted to Ischemia Damaged Myocardium in Humans: Histological Analysis of Cell Survival and Differentiation. Journal of the American College of Cardiology, 41, 879-888.
http://dx.doi.org/10.1016/S0735-1097(03)00081-0
[66]  Menasche, P., Vilquin, J.T. and Desnos, M. (2001) Early Results of Autologous Skeletal Myoblast Transplantation in Patients with Severe Ischemic Heart Failure. Circulation, 104, 213-217.
[67]  Menasché, P., Hagège, A.A., Scorsin, M., Pouzet, B., Desnos, M., Duboc, D., et al. (2001) Myoblast Transplantation for Heart Failure. The Lancet, 357, 279-280.
http://dx.doi.org/10.1016/S0140-6736(00)03617-5
[68]  Menasche, P., Hagege, A.A., Vilquin, J.T., et al. (2003) Autologous Skeletal Myoblast Transplantation for Severe Postinfarction Left Ventricular Dysfunction. Journal of the American College of Cardiology, 41, 1078-1083.
http://dx.doi.org/10.1016/S0735-1097(03)00092-5
[69]  Menasché, P., Alfieri, O., Janssens, S., McKenna, W., Reichenspurner, H., Trinquart, L., et al. (2008) The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial. Circulation, 117, 1189-1200.
http://dx.doi.org/10.1161/CIRCULATIONAHA.107.734103
[70]  Dib, N., Michler, R.E., Pagani, F.D., Wright, S., Kereiakes, D.J., Lengerich, R., et al. (2005) Safety and Feasibility of Autologous Myoblast Transplantation in Patients with Ischemic Cardiomyopathy. Four Year Follow-Up. Circulation, 112, 1748-1755.
http://dx.doi.org/10.1161/CIRCULATIONAHA.105.547810
[71]  Dib, N., Dinsmore, J., Lababidi, Z., White, B., Moravec, S., Campbell, A., et al. (2009) One-Year Follow-Up of Feasibility and Safety of the First U.S., Randomized, Controlled Study Using 3-Dimensional Guided Catheter-Based Delivery of Autologous Skeletal Myoblasts for Ischemic Cardiomyopathy (CAuSMIC Study). JACC: Cardiovascular Interventions, 2, 9-16.
http://dx.doi.org/10.1016/j.jcin.2008.11.003
[72]  Veltman, C.E., Soliman, O.I., Geleijnse, M.L., Vletter, W.B., Smits, P.C., ten Cate, F.J., et al. (2008) Four-Year Follow-Up of Treatment with Intramyocardial Skeletal Myoblasts Injection in Patients with Ischaemic Cardiomyopathy. European Heart Journal, 29, 1386-1396.
http://dx.doi.org/10.1093/eurheartj/ehn171
[73]  Thomas, J.P., O’Connor, C.M., Henry, T., Taussig, A., Kereiakes, D.J., Fortuin, F.D., et al. (2011) A Double-Blind, Randomized, Controlled, Multicenter Study to Assess the Safety and Cardiovascular Effects of Skeletal Myoblast Implantation by Catheter Delivery in Patients with Chronic Heart Failure after Myocardial Infarction. American Heart Journal, 162, 654-662.
http://dx.doi.org/10.1016/j.ahj.2011.07.020
[74]  Smits, P.C., van Geuns, R.J., Poldermans, D., et al. (2003) Catheter-Based Intramyocardial Injection of Autologous Skeletal Myoblasts as a Primary Treatment of Ischemic Heart Failure: Clinical Experience with Six-Month Follow-Up. Journal of the American College of Cardiology, 42, 2063-2069.
http://dx.doi.org/10.1016/j.jacc.2003.06.017
[75]  Gavira, J.J., Herreros, J., Perez, A., Garcia-Velloso, M.J., Barba, J., Martin-Herrero, F., et al. (2006) Autologous Skeletal Myoblast Transplantation in Patients with Nonacute Myocardial Infarction: 1-Year Follow-Up. The Journal of Thoracic and Cardiovascular Surgery, 131, 799-804.
http://dx.doi.org/10.1016/j.jtcvs.2005.11.030
[76]  Herrerosa, J., Prósperb, F., Perezb, A., Gaviraa, J.J., Garcia-Vellosoc, M.J., Joaquín Barbaa, J., et al. (2003) Autologous Intramyocardial Injection of Cultured Skeletal Muscle-Derived Stem Cells in Patients with Non-Acute Myocardial Infarction. European Heart Journal, 24, 2012-2020.
http://dx.doi.org/10.1016/j.ehj.2003.09.012
[77]  Siminiak, T., Fiszer, D., Jerzykowska, O., Grygielska, B., Rozwadowska, N., Kalmucki, P. and Kurpisz, M. (2005) Percutaneous Trans-Coronary-Venous Transplantation of Autologous Skeletal Myoblasts in the Treatment of Post-Infarction Myocardial Contractility Impairment: The POZNAN Trial. European Heart Journal, 26, 1188-1195.
http://dx.doi.org/10.1093/eurheartj/ehi159
[78]  Ince, H., Petzsch, M., Rehders, T.C., Chatterjee, T. and Nienaber, C.A. (2004) Transcather Transplantation of Autologous Skeletal Myoblasts in Postinfarction Patients with Severe Left Ventricular Dysfunction. Journal of Endovascular Therapy, 11, 695-704.
http://dx.doi.org/10.1583/04-1386R.1
[79]  Law, P.K., Fang, G. and Chua, F. (2003) First-in-Man Myoblast Allografts for Heart Degeneration. International Journal of Medical Implants and Devices, 1, 100-155.
[80]  Rosinberg, A., Rana, J.S. and Laham, R.J. (2005) Skeletal Myoblast Transplantation for Cardiac Repair. In: Laham, R.J. and Baim, D.S., Eds., Direct Myocardial Revascularization Contemporary Cardiology, Springer, New York, 311-328.
http://dx.doi.org/10.1007/978-1-59259-934-9_12
[81]  James, D.E., Brown, R., Navarro, J. and Pilch, P.F. (1988) Insu-lin-Regulatable Tissues Express a Unique Insulin-Sen- sitive Glucose Transport Protein. Nature, 333, 183-185.
http://dx.doi.org/10.1038/333183a0
[82]  James, D.E., Strube, M. and Mueckler, M. (1989) Molecular Cloning and Characterization of an Insulin-Regulatable Glucose Transporter. Nature, 338, 83-87.
http://dx.doi.org/10.1038/338083a0
[83]  Cushman, S.W. and Wardzala, L.J. (1980) Potential Mechanism of Insulin Action on Glucose Transport in the Isolated Rat Adipose Cell. Apparent Translocation of Intracellular Transport Systems to the Plasma Membrane. The Journal of Biological Chemistry, 255, 4758-4762.
[84]  Stenbit, A.E., Tsao, T.S., Li, J., Burcelin, R., Geenen, D.L., Factor, S.M., et al. (1997) GLUT4 Heterozygous Knockout Mice Develop Muscle Insulin Resistance and Diabetes. Nature Medicine, 3, 1096-1101.
http://dx.doi.org/10.1038/nm1097-1096
[85]  Morgan, B.J., Chai, S.Y. and Albiston, A.L. (2011) GLUT4 Associated Proteins as Therapeutic Targets for Diabetes. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, 5, 25-32.
http://dx.doi.org/10.2174/187221411794351914
[86]  Zisman, A., Peroni, O.D., Abel, E.D., et al. (2000) Targeted Disruption of the Glucose Transporter 4 Selectively in Muscle Causes Insulin Resistance and Glucose Intolerance. Nature Medicine, 6, 924-928.
http://dx.doi.org/10.1038/78693
[87]  Koh, H.J., Arnolds, D.E., Fujii, N., et al. (2006) Skeletal Muscle-Selective Knockout of LKB1 Increases Insulin Sensitivity, Improves Glucose Homeostasis, and Decreases TRB3. Molecular and Cellular Biology, 26, 8217-8227.
http://dx.doi.org/10.1128/MCB.00979-06
[88]  Saltiel, A.R. (2001) New Perspectives into the Molecular Pathogenesis and Treatment of Type 2 Diabetes. Cell, 104, 517-529.
http://dx.doi.org/10.1016/S0092-8674(01)00239-2
[89]  Law, P.K. Myoblast Therapy for Cosmetic Treatment. US7341719 (2008), SI99279 (2004), CN03101588 (2003).
[90]  Law, P.K. Biologic Skin Repair and Enhancement. WO017972 (2004), CN03819963 (2008), SI110581 (2007).
[91]  Masato, I. and Satoshi, A. (2009) Fibroblast Proliferators. EP2110123. (German) (French)
[92]  Alexander, M.H., Ross, H.I., Anthony, J.K., Sanjay, M., Darin, J.M., Agnieszka, S., et al. (2005) Soft Tissue Repair and Regeneration Using Postpartum-Derived Cells. US2005058629.
[93]  Law, P.K. (2009) Pioneering Human Myoblast Genome Therapy. Nova Science, New York.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133